GLP-1 receptor agonists have been successfully used clinically for T2DM treatment, whereas GIP levels are increased in individuals with obesity and T2DM (Tasyurek et al., 2014; Holst and Rosenkilde, 2020). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.